Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
Status:
Completed
Trial end date:
2017-11-21
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to evaluate the effect of 24 weeks of evolocumab
administered subcutaneously (SC) every month, compared with ezetimibe, on low-density
lipoprotein cholesterol (LDL-C) levels in adults with high cholesterol who are unable to
tolerate an effective dose of a statin due to muscle-related side effects (MRSE).